A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by a Seasonal Trivalent Influenza Vaccine (TIV)
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BiondVax Pharmaceuticals
- 23 Aug 2015 Status changed from recruiting to completed, according to a BiondVax media release.
- 29 Jun 2015 Preliminary results published in a BiondVax Media Release.
- 21 Nov 2014 New trial record